Dose-dependent impact of tixagevimab–cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals

Dose-dependent impact of tixagevimab–cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals

Abstract Tixagevimab–cilgavimab was available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevention from December 2021 to January 2023, with dosing changes to reflect circulating variants. In a retrospective analysis of 597 immunocompromised individuals, incidence of SARS-CoV-2...

Full description

Saved in:

Bibliographic Details
Main Authors:	Daniela Dluzynski, Paddy Ssentongo, Cory M. Hale, Shareef K. Shaheen, Natella Maglakelidze, Jeffrey M. Sivik, Maria Paula Henao, Vernon M. Chinchilli, Catharine I. Paules
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-05-01
Series:	Scientific Reports
Subjects:	COVID-19 Tixagevimab–cilgavimab Monoclonal antibody Hematopoietic stem cell transplant Chimeric antigen receptor (CAR)-T cell therapy
Online Access:	https://doi.org/10.1038/s41598-025-02240-3
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-world clinical outcomes of tixagevimab/cilgavimab in the Omicron outbreak in China: baseline characteristics and interim analysis of the CLEAR study
by: Jianhua You, et al.
Published: (2024-10-01)

Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study
by: Jassada Buaboonnam, et al.
Published: (2024-12-01)

Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy
by: M. V. Zhuravleva, et al.
Published: (2023-07-01)

Experience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab
by: T. V. Beketova, et al.
Published: (2023-04-01)

Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results
by: T. V. Beketova, et al.
Published: (2024-11-01)

Effectiveness of pharmacological treatments for COVID-19 due to SARS-CoV-2: a systematic literature review
by: Carolina Garcia Vidal, et al.
Published: (2025-02-01)

Experience with the use of thixagevimab/cilgavimab for pre-exposure prophylaxis of COVID-19 in patients with HIV infection in the Omsk region
by: M. V. Balabokhina, et al.
Published: (2023-04-01)

Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19
by: Mostafa Hossam El Din Moawad, et al.
Published: (2025-06-01)

Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies
by: Rachel A. Bender Ignacio, et al.
Published: (2025-03-01)

Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective
by: Paul Loubet, et al.
Published: (2025-03-01)

Clinical outcomes in kidney transplant recipients receiving tixagevimab/cilgavimab for outpatient treatment of COVID-19: a single-center retrospective study
by: Bilgin Osmanodja, et al.
Published: (2025-06-01)

Current opportunities to improve outcomes of COVID-19 infection prevention and course in patients with lymphoproliferative diseases (regional analysis)
by: Ch. Kh. Valiakhmetova, et al.
Published: (2023-05-01)

Hepatic T cell lymphoma after chimeric antigen receptor T cell therapy for myeloma
by: Joshua Mehr, et al.
Published: (2024-12-01)

Mixed T-Cell Chimerism Following Hematopoietic Cell Transplantation for Non-Malignant Disorders Is Common, Facilitates Anti-Viral Immunity, and Is Not Associated with Graft Failure in Pediatric Patients
by: Rubiya Nadaf, et al.
Published: (2024-12-01)

Sudden death in individuals with obstructive sleep apnoea: a systematic review and meta-analysis
by: Vernon M Chinchilli, et al.
Published: (2021-01-01)

Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period
by: Samah Hayek, et al.
Published: (2025-01-01)

Village-level climate and weather variability, mediated by village-level crop yield, is associated with linear growth in children in Uganda
by: Vernon M Chinchilli, et al.
Published: (2020-10-01)

The prognostic value of posttransplant chimerism
by: A. A. Sipol, et al.
Published: (2022-11-01)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)

The use of T-cells with chimeric antigen receptor (CAR-T) in combination with chemotherapy and radiotherapy for the treatment of solid tumors
by: M. R. Khaliulin, et al.
Published: (2024-04-01)

The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer
by: Hao-Yu Tang, et al.
Published: (2025-01-01)

Targeting TGFβ with chimeric switch receptor and secreted trap to improve T cells anti-tumor activity
by: Tatyana Matikhina, et al.
Published: (2024-10-01)

Adoptitive immunotherapy with genetically engineered T lymphocytes modified to express chimeric antigen receptors
by: A. А. Pavlova, et al.
Published: (2017-04-01)

Co-expression of a truncated TGFβ receptor II in c-Met CAR T cells enhances antitumor activity against lung adenocarcinoma
by: Chao Su, et al.
Published: (2025-08-01)

Targeting BCMA in multiple myeloma: designs, challenges, and future directions
by: Yi Hu, et al.
Published: (2025-02-01)

Effects of Mesenchymal Stem Cells on Functions of Chimeric Antigen Receptor-Expressing T Lymphocytes and Natural Killer Cells
by: Vladislav Volarevic, et al.
Published: (2025-06-01)

An integral membrane constitutively active heparanase enhances the tumor infiltration capability of NK cells
by: Sofia Liborio-Ramos, et al.
Published: (2025-12-01)

Does a natural killer need a CAR?
by: Kangbo Wang, et al.
Published: (2025-06-01)

Preparation of Trop2-targeted chimeric antigen receptor T cells and study of their exhaustion status in vitro
by: LIU Xiuying, et al.
Published: (2025-08-01)

Differential susceptibility and role for senescence in CART cells based on costimulatory domains
by: Ismail Can, et al.
Published: (2025-06-01)

Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia
by: Wenyue Cao, et al.
Published: (2025-04-01)

CAR‐NK, a Splendid Strategy for Cancer, Especially for Gynecologic Tumor
by: Yisen Cao, et al.
Published: (2025-06-01)

Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma
by: Sijia Yan, et al.
Published: (2025-03-01)

Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma
by: Sahand Saeidpour Masouleh, et al.
Published: (2025-05-01)

Transduction of γδ T cells with Baboon envelope pseudotyped lentiviral vector encoding chimeric antigen receptors for translational and clinical applications
by: Lorraine Pinot, et al.
Published: (2025-06-01)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
by: Lina Zhang, et al.
Published: (2021-01-01)

Enhancing the physiological characteristics of chimeric antigen receptor natural killer cells by synthetic biology
by: Shuochao Ji, et al.
Published: (2025-04-01)

Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases
by: Alejandrina Hernández-López, et al.
Published: (2025-01-01)

InDel polymorphisms in quantitative posttransplant chi merism evaluation
by: I. M. Barkhatov, et al.
Published: (2016-12-01)

The Current Use of Biomedical Cell Products for Cancer Treatment
by: E. A. Ustyugova, et al.
Published: (2019-12-01)